Ibrutinib with rituximab in previously untreated CLL: Indication of added benefit over FCR

The combination of ibrutinib plus rituximab is approved for the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL). In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) now examined which advantages and disadvantages this drug combination has for the patients. For patients who could also be […]

Continue Reading

U.S. factory orders beat expectations in November

New orders for U.S.-made goods increased more than expected in November and business investment on equipment was solid, pointing to sustained recovery in manufacturing. The Commerce Department said on Wednesday that factory orders rose 1.0% after increasing 1.3% in October. Economists poll had forecast factory orders increasing 0.7% in November. Orders fell 7.3% year-on-year. Manufacturing, […]

Continue Reading

New clues to prostate cancer: Why aggressive subtype can resist treatment

Australian research has identified a new mechanism in which prostate cancer cells can ‘switch’ character and become resistant to therapy. These findings, just published in Cell Reports, are an important development in unraveling how an aggressive subtype of prostate cancer, neuroendocrine prostate cancer (NEPC), develops after hormonal therapies. It is well established that some tumors […]

Continue Reading

UnitedHealth to buy Change Healthcare for nearly $8 billion to boost tech services

Health insurer UnitedHealth Group on Wednesday agreed to buy Change Healthcare for $7.84 billion in an all-cash deal, as it looks to expand its fast-growing healthcare technology business. UnitedHealth will pay $25.75 per Change Healthcare share, a premium of 41.2% to Tuesday’s closing price. Shares of Change, which will merge with UnitedHealth unit Optum, were […]

Continue Reading